EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Traws Pharma's enterprise value is $-5.12 Mil.
Traws Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-20.28 Mil. Therefore, Traws Pharma's EV-to-EBITDA for today is 0.25.
The historical rank and industry rank for Traws Pharma's EV-to-EBITDA or its related term are showing as below:
TRAW'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.82 Med: -0.17 Max: 1.71
Current: 0.25
During the past 13 years, the highest EV-to-EBITDA of Traws Pharma was 1.71. The lowest was -17.82. And the median was -0.17.
TRAW's EV-to-EBITDA is ranked better than 87.71% of 472
companies
in the Biotechnology industry
Industry Median: 9.095
vs TRAW: 0.25
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Traws Pharma EV-to-EBITDA Historical Data
The historical data trend for Traws Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Traws Pharma's EV-to-EBITDA
For the Biotechnology subindustry, Traws Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Traws Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Traws Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Traws Pharma's EV-to-EBITDA falls into.
Traws Pharma EV-to-EBITDA Calculation
Traws Pharma's EV-to-EBITDA for today is calculated as:
Traws Pharma's current Enterprise Value is $-5.12 Mil.
Traws Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma (NAS:TRAW) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Traws Pharma's PE Ratio for today is calculated as:
Traws Pharma's share price for today is $0.64.
Traws Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.910.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Traws Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRAW has been successfully added to your 